Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. J of Skin 2020, 4 (6), s82. https://doi.org/10.25251/skin.4.supp.82.